Gastric cancer-derived exosomal indoleamine 2,3 dioxygenase 1 drives immunosuppression in gastric cancer by suppressing dendritic cell maturation
World Journal of Gastroenterology · 28.07.2026 · 32 (28)
DOI: 10.3748/wjg.118939 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 28.07.2026. Verfasst von Yang-Yang Liu und 4 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Indoleamine 2,3 dioxygenase 1 (IDO1) restrains the functions of dendritic cells (DCs) and T cells, reinforcing the immunosuppressive microenvironment. Owing to its established role as an oncogene in gastric cancer, understanding how IDO1 modulates antitumor immunity is critical. AIM To elucidate the roles of gastric cancer-derived exosomal IDO1 in regulating DC maturation and antitumor immune response in gastric cancer. METHODS IDO1 protein expression in gastric cancer tissues and cell lines was examined. Exosomes from gastric cancer line (MKN45) were isolated. Bone marrow-derived DCs were exposed to lipopolysaccharide and then treated with unmodified or IDO1-silenced exosomes. The maturation status of DCs was subsequently analyzed by measuring the surface expression of key markers cluster of differentiation (CD) 80, CD86, and major histocompatibility complex class II (MHC II) and the secretion of cytokines interleukin (IL)-12p70 and IL-10. Furthermore, a subcutaneous tumor mouse model was established and injected with unmodified or IDO1-silenced exosomes. Tumor growth, DC maturation, and T cell activation were also systematically evaluated. RESULTS IDO1 was upregulated in gastric cancer tissues and enriched in gastric cancer cell-derived exosomes. Treatment with these exosomes suppressed DC maturation, as evidenced by significant reductions in the expression of CD80, CD86, and MHC II at approximately 63%, 62%, and 70%, respectively; approximately 60% decrease in IL-12p70; and more than 178% increase in IL-10. IDO1 silencing in exosomes reversed these effects. In vivo administration of unmodified exosomes inhibited DC maturation (CD80, CD86, and MHC II expression levels reduced by 55%, 64%, and 65%, respectively) and T-cell activation, thereby promoting tumor growth in mice (tumor weight increased by 1.9 folds). Treatment with IDO1-silenced exosomes restored these effects and attenuated tumor growth (tumor weight reduced by approximately 67%). CONCLUSION Gastric cancer-derived exosomal IDO1 drives immunosuppression in gastric cancer by suppressing DC maturation. Our findings deepen the comprehension of gastric cancer immune evasion and propose IDO1 as a promising therapeutic target.
Zitieren
APA
Liu, Y., Ai, J., Zeng, L., Liu, X., & Wu, F. (2026). Gastric cancer-derived exosomal indoleamine 2,3 dioxygenase 1 drives immunosuppression in gastric cancer by suppressing dendritic cell maturation. World Journal of Gastroenterology, 32(28). https://doi.org/10.3748/wjg.118939
Vancouver
Liu Y, Ai J, Zeng L, Liu X, Wu F. Gastric cancer-derived exosomal indoleamine 2,3 dioxygenase 1 drives immunosuppression in gastric cancer by suppressing dendritic cell maturation. World Journal of Gastroenterology. 2026;32(28). doi:10.3748/wjg.118939
BibTeX
@article{Liu2026,
author = {Liu, Yang-Yang and Ai, Jun-Hua and Zeng, Le-Ming and Liu, Xue-Ni and Wu, Fang},
title = {Gastric cancer-derived exosomal indoleamine 2,3 dioxygenase 1 drives immunosuppression in gastric cancer by suppressing dendritic cell maturation},
journal = {World Journal of Gastroenterology},
year = {2026},
volume = {32},
number = {28},
doi = {10.3748/wjg.118939}
}
EUVIMED